Infertility of Uterine Origin Clinical Trial
Official title:
Deceased Uterine Transplant in Absolute Uterine Infertility (AUIF)
Our study will explore the feasibility of initiating a deceased donor uterine transplant
program in addition to the existing living donor IRB at BWH.
Using the template established by teams around the world, we will identify emotionally and
socially stable females of reproductive age with intact ovaries who are unable to gestate a
child due to congenital or acquired uterine factor infertility. After careful screening,
participants will undergo egg harvest, in vitro fertilization, and embryo cryopreservation
using standard methods. Women who successfully complete the fertilization of at least six
euploid embryos will be eligible to be placed on the waitlist for a deceased donor uterus
transplant. After a successful transplant and a period of observation to ensure normal
menstrual cycle and graft viability (anticipate six months), embryo implantation will be
undertaken.
Following an embryo transfer, gestation will be carefully monitored by our high-risk
pregnancy specialists. Medical research interventions include the surgical implantation of a
uterus utilizing techniques by teams that have applied this approach successfully, close
post-transplant follow up including immunosuppression therapy tailored to established
standards during pregnancy minimizing fetal risks, and careful management of pregnancy. After
childbearing is complete (at most two gestations), the donor uterus will be removed either
during Cesarean or during an elective procedure. In addition, open ended interviews and
surveys will be conducted to elicit ethical and psychosocial concerns arising from the
experience of subjects and their families, health care providers, and the wider community.
The investigator's intent is to monitor outcomes for transplant recipients as well as the
live born infants for 30 days after removal of the transplanted uterus.
It is estimated that the time from screening to a potential live birth will be a minimum of
22 months, but likely between 24 - 36 months depending on organ availability.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05538338 -
Platelet Rich Plasma for Insufficient Endometrium
|
N/A | |
Terminated |
NCT03530254 -
Clinical Study of PGT-A Versus PGT-A+ERA
|
N/A | |
Recruiting |
NCT06174298 -
The Role of Granulocyte Colony Stimulating Factor in Embryo Transfer Outcomes
|
Phase 4 | |
Recruiting |
NCT05263076 -
Uterine Transplant for Women With Absolute Uterine Factor Infertility (AUFI)
|
N/A | |
Recruiting |
NCT04554654 -
Progesterone Levels and Endometrial Compaction in Frozen-Thawed Embryo Transfer Cycles
|
||
Terminated |
NCT04045821 -
Endometrial Rejuvenation Study
|
N/A | |
Recruiting |
NCT06097559 -
International Non-selection Study for ERA® Test in Patients With Previous Implantation Failures
|
||
Completed |
NCT03166189 -
Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF Failures
|
Phase 2 | |
Completed |
NCT03330444 -
Development of a Microbiome Non-invasive Diagnosis Tool
|